Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Subscribe To Our Newsletter & Stay Updated
